[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.
Eur J Nucl Med Mol Imaging
; 47(5): 1239-1251, 2020 05.
Article
in En
| MEDLINE
| ID: mdl-31754793
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Paclitaxel
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Eur J Nucl Med Mol Imaging
Journal subject:
MEDICINA NUCLEAR
Year:
2020
Document type:
Article
Affiliation country: